Aurobindo Pharma has received approval for Montelukast Sodium Oral Granules USP, 4mg
Published: July 31, 2020
East Windsor, NJ–Aurobindo Pharma has received approval from the U.S. Food and Drug Administrationfor its Abbreviated New Drug Application Montelukast Sodium Oral Granules USP, 4mg. Aurobindo’s Montelukast Sodium Oral Granules USP, 4 mg are an AB-rated generic equivalent to the reference listed drug (RLD),SINGULAIR® of Merck & Co Inc. They will be available in 4 mg dose presentations.